TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diffuse large B-cell lymphoma~  * B-cell phenotype (CD20+) as determined by immunohistochemistry (IHC) or flow cytometry~ * Stage II, III, or IV disease~* CD22+ tumor by IHC\*~NOTE: \*CD22 status may be determined after study enrollment~* Measurable disease, defined as at least 1 lesion ≥ 1.5 cm by CT scan or physical exam~* No relapsed or refractory non-Hodgkin's lymphoma~* No history of transformed lymphoma~* No CNS lymphoma~  * CNS symptoms or bone marrow or sinus involvement must have absence of CNS lymphoma confirmed by lumbar puncture~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3~  - For patients with ECOG PS 3, the PS must be disease related~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Total bilirubin ≤ 2 mg/dL (if total bilirubin \> 2 mg/dL, direct bilirubin should be within normal limits)~* AST ≤ 3 times upper limit of normal (ULN) (5 times ULN if there is liver involvement)~* Creatinine ≤ 2 times ULN~* Life expectancy ≥ 12 weeks~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* No active serious infection requiring antibiotics~* No New York Heart Association class III or IV heart disease~* No other primary malignancy within the past 5 years, except for squamous cell or basal cell carcinoma of the skin, in situ carcinoma of the cervix, or previously treated prostate cancer with a stable prostate-specific antigen~* No known HIV positivity~* No known hepatitis B or C infection~* Ejection fraction ≥ 45% by MUGA or echocardiogram (required if patients has a history of heart disease or is ≥ 50 years old)~* Willing to provide blood and tissue samples for mandatory translational research component of study~PRIOR CONCURRENT THERAPY:~* No prior therapy for diffuse large B-cell lymphoma, including the following:~  * Chemotherapy~ * Immunotherapy~ * Biologic therapy~ * Radiotherapy~* Prior short course (≤ 14 days) of corticosteroids allowed~* Prior splenectomy allowed~* No prior pelvic irradiation~* No other concurrent investigational agents~* No concurrent chemotherapy, immunotherapy, or radiotherapy~* No concurrent enrollment on another treatment study involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, or gene therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epratuzumab + Rituximab + CHOP (Type: EXPERIMENTAL): One arm open label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Antibiotics in Measles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of probable measles in the prodromal phase or within the first seven days of the onset of the rash~Exclusion Criteria:~* Pregnant and nursing women~* Children less than 2 months old~* Children who need urgent referral to the hospital, children with bacterial infections of the lung, or children with another bacterial infection requiring systemic antibiotic treatment.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient ≥ 18 years~2. Philadelphia chromosome positive newly diagnosed chronic myelogenous leukaemia (≤ 4 months) in first chronic phase.~3. Not previously treated with tyrosine kinase inhibitors other than imatinib~4. Prior treatment with imatinib during less than 13 weeks~5. Signed written inform consent~6. Women of childbearing potential (WOCBP) must be using an adequate method of contraception~Exclusion Criteria:~1. Patients with BCR-ABL positive, Philadelphia negative CML~2. Patient previously treated with TKI other than imatinib~3. Pregnancy~4. Active malignancy~5. Concurrent severe diseases which exclude the administration of therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: NO_INTERVENTION): cohort 3: Imatinib through dosage ≥ 1000 ng/ml
- Active comparator (Type: ACTIVE_COMPARATOR): Cohort 2 : Imatinib standard dose Imatinib through dosage \< 1000 ng/ml
- Experimental arm (Type: EXPERIMENTAL): Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage \< 1000 ng/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Marginal Bone and Soft Tissue Alterations After Use of OsseoSpeed EV Profile Implants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* lack of tooth in position of central incisors, canines and premolars~Exclusion Criteria:~* Smoking~* Uncontrolled diabetes~* Pregnancy or lactation~* Poor oral hygiene~* Compromised dentition neighboring to edentulous site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group with implants (Type: EXPERIMENTAL): Flap will be elevated following the crestal and releasing incisions (if necessary).~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women \>=18 years of age~* Diagnosis of Crohn's~* Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis, confirmed by radiography or endoscopy~Exclusion Criteria:~* Local manifestations of Crohn's disease such as strictures, abscesses, or other disease~* Surgery for bowel diversion with placement of a stoma within 3 months prior to beginning the study~* Positive stool culture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 6 weeks to 59 months~* Residence in the study area~* Informed consent~Exclusion Criteria:~* Known allergy to study drugs~* Serious underlying illness

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 59 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Antiretroviral (ARV) Drug Levels in Dried Blood Spots (DBS) to Assess and Manage ART Adherence in South Africa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* HIV-positive~* Initiated ARV's containing tenofovir 4 or more months ago~* Speaks English or Xhosa~* Willing to attend 5 study visits approximately one month apart~* Willing to allow the study team to contact his/her HIV care provider about his/her monthly TFV-diphosphate (TFV-DP) drug level~* Willing to use Wise Pill to dispense ARVs for 4 months~* Willing to receive text/short message service (SMS) and/or phone call reminders to charge the Wise Pill~* Willing to allow the study team access to their medical chart/clinic folder~Exclusion Criteria:~* Unable to provide informed consent~* Unwilling to participate in study procedures~* Unwilling to allow the study team to contact his/her HIV care provider about his/her monthly TFV-DP drug level~* Any condition that, in the opinion of the principal investigator would make participation in the study unsafe, complicated interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Receiving Feedback From DBS (Type: EXPERIMENTAL): This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years old with refractory/relapsed AML~  * If untreated AML, patient is older than 60 years old and not a candidate for standard chemotherapy~* Patient is at least 4 weeks from prior treatment and has recovered from all prior treatment side effects~* Patient has no known liver or kidney problems~* Patient knows of no reason they can not receive transfusions of blood clotting cells (platelets)~* Patient is able to swallow capsules~* Patients both male and female are willing to practice birth control during the study~Exclusion Criteria:~* Patient has received prior treatment with valproic acid, decitabine or azacitidine~* Being is less than 18 years of age or if patient has untreated AML is below 60 years of age~* Patient is a women who is pregnant or breastfeeding. Patient has an active infection that requires antibiotics~* Patient has uncontrolled illness including but not limited to the following: heart problems (congestive heart failure, unstable angina pectoris, cardiac arrhythmia), inflammation of the pancreas; a mental or social condition that may interfere with patient following study procedures~* Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy. Patient has a known history of hepatitis B or C infection~* Patient currently has another active cancer other than certain types of skin cancer~* Patient is heterosexual and able to have a child and is unwilling to practice birth control during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vorinostat (sequential) (Type: EXPERIMENTAL): Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.
- Cohort 2: Vorinostat (concurrent) (Type: EXPERIMENTAL): Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Intraoperative Esmolol in Mastectomies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, aged 18 to 75 years, electively scheduled to perform mastectomy in the Base Hospital of the Federal District;~* Physical State 1 or 2 the American Society of Anesthesiology (ASA);~Exclusion Criteria:~* Patients under the age of 18 years and above 75 years;~* Patients with unstable angina~* Patient with poorly controlled asthma~* Substance abuse~* Sinus bradycardia~* Heart failure, greater than first degree atrioventricular block~* Pregnant women~* Patients with allergy to dipyrone, morphine;~* Patients with chronic pain;~* Patients with severe hepatic disease;~* Patients with severe kidney disease;~* Patients with neurological diseases;~* Included patients in other clinical studies currently or in the past three months under general anesthesia;~* Patients who refuse to participate in the study;~* Any other condition that, in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
- Esmolol group (Type: ACTIVE_COMPARATOR): Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Bacterial Vaginosis With Oral Tinidazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Clinical and microbiological diagnosis of bacterial vaginosis -~Exclusion Criteria:~Other sexually transmitted disease~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for the study, a child must meet the following criteria:~1. Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic criteria~2. Time since diagnosis of no longer than one month~3. Age between 2 and 17 years~4. Parental consent (and assent from the child where applicable) to participate in the study~5. No severe medical conditions, which in the opinion of the investigators are likely to hinder participation in this clinical trial.~To be eligible for the study, a parent must meet the following criteria:~1. Parent or legal guardian of a child with type 1 diabetes meeting the child criteria outlined above~2. Age of 18.0 years or older~3. Parent comprehends written English~4. Parent understands the study protocol and signs the informed consent document~Exclusion Criteria:~The presence of any of the following is an exclusion for the study:~1. Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).~2. Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol~3. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study~4. Child is unable to completely avoid acetaminophen for duration of study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- CGM at diagnosis of T1D (Type: EXPERIMENTAL): Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
- Usual Care (Type: NO_INTERVENTION): Participants receive usual care for T1D for 6 months post diagnosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants between 18-65 years of age with moderately to severely (Crohn's Disease Activity Index 220-450) active Crohn's Disease with or without fistula formation~* Participants who were able to provide authorization to use and disclose information related to the study~* Proven diagnosis of Crohn's Disease in accordance with international diagnostic criteria such as European Crohn's and Colitis Organization (ECCO) guidelines~* Participants for whom the physician had initiated anti-Tumor Necrosis Factor treatment in accordance with Turkish Ministry of Health regulations and reimbursements~Exclusion Criteria:~* Participants who had a history of any kind of biological therapy and/or anti-Tumor Necrosis Factor treatments for Crohn's Disease or other indications~* Participants who had septic complications (active infection and/or active tuberculosis (TB), undrained abscess)~* Participants who had bowel obstructions and fibrotic strictures~* Participants who had received any investigational drug within 30 days prior to the Visit 1 at baseline~* For any reason, participants who were considered by the investigator to be unsuitable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Participants with moderate to severe Crohn's Disease (Type: None): Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stepped Care to Optimize Pain Care Effectiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~SCOPE will enroll 250 primary care veterans with persistent (3 months or longer) musculoskeletal pain of moderate severity and randomize them to either the stepped care intervention or usual care control group.~Exclusion Criteria:~Individuals who:~* have filed a pain-related disability claim in the last 6 months;~* do not speak English;~* have moderately severe cognitive impairment;~* have schizophrenia, bipolar disorder, or other psychosis;~* are actively suicidal;~* have current illicit drug use; or~* have an anticipated life expectancy of less than 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Stepped Care (Type: EXPERIMENTAL): Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
- Usual Care (Type: NO_INTERVENTION): Patients receive usual care for pain from their primary care physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete